C3 and complement 3 glomerulopathy: Additionally, the FDA recently approved Pegcetacoplan, a C3 inhibitor, for paroxysmal nocturnal hematuria and phase II trials are currently ongoing regarding use in kidney transplant recipients with recurrent C3 glomerulopathy (NCT04572854).